Novartis ADR Stock News

A new antimalarial drug developed by Novartis is as effective as existing treatments and could help tackle rising drug resistance, the company said on Wednesday as it presented final-stage trial results.

Swiss drugmaker Novartis said on Monday it has opened a new 10,000-square-foot factory in Carlsbad, California, to make cancer treatments, as part of its pledge to invest billions into building U.S. sites.

Basel, November 4, 2025 – Novartis will present new data from 33 abstracts across its Cardiovascular, Renal, and Metabolic (CRM) disease portfolio at the upcoming American Society of Nephrology (ASN) Kidney Week 2025 in Houston, Texas and American Heart Association's (AHA) Scientific Sessions 2025 in New Orleans, Louisiana, advancing scientific insight into these critical disease areas. “Novart...

NASHVILLE, Tenn.--(BUSINESS WIRE)--The School of Global Health at Meharry Medical College, in partnership with Novartis, today announced the launch of Health Assessments and Rapid Transformation (HEART), a five-year initiative that aims to improve heart health in three US cities through population health approaches addressing clinical and non-clinical determinants of health. Guided by community...

Novartis AG ( NVS ) Discusses Immunology Portfolio Update and Advances in Autoimmune Therapies October 30, 2025 11:30 AM EDT Company Participants Isabella Zinck Shreeram Aradhye - President of Development & Chief Medical Officer Victor Bulto - President of US Angelika Jahreis Conference Call Participants Simon Baker - Rothschild & Co Redburn, Research Division Thibault Boutherin - Morgan Stanle...

Basel, October 29, 2025 – Novartis today presented new ianalumab data in Sjögren's disease, the second most prevalent rheumatic autoimmune disease2, at a late-breaker presentation during the American College of Rheumatology Convergence congress1.

The market continues to trade deeper in overbought territory based on most traditional valuation metrics. Most of the gains over the past three years have been driven by tech giants riding the AI Revolution higher. Equities continue to hit all-time highs even the government shut down has nearly hit the one month mark and trade tensions remain between China and the U.S.

Novartis AG (NYSE:NVS ) Q3 2025 Earnings Call October 28, 2025 9:00 AM EDT Company Participants Sloan Simpson - Global Head of Investor Relations Vasant Narasimhan - Chief Executive Officer Harry Kirsch - Chief Financial Officer Conference Call Participants Matthew Weston - UBS Investment Bank, Research Division Peter Verdult - BNP Paribas Exane, Research Division Steve Scala - TD Cowen, Resear...